Axicabtagene ciloleucel – VJRegenMed

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy

Thu, 26 Jan 2023 12:12:01 +0000

Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>

Engineering NK cell-based cancer treatments

Tue, 12 Apr 2022 11:18:06 +0000

Juliane Mietz, University Of Zurich, Zurich, Switzerland, comments on ongoing research to develop anti-cancer natural killer (NK) cell therapies. Chimeric antigen receptor (CAR)-NK cells were initially studied alongside CAR T-cell, where both were engineered with CD28 or a 4-1BB costimulatory domains, domains found in axicabtagene ciloleucel and tisagenlecleucel, to assess the clinical efficacy of CAR-NK cells. Further pre-clinical studies involving CAR-NK cells are additionally underway to enhance their cytotoxicity in patients. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

]]>

CAR-T in DLBCL: 4-year follow-up data from ZUMA-1

Fri, 26 Feb 2021 14:08:28 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore, there were no additional toxicity signs reported in this long-term follow-up analysis. This interview took place during the 3rd European CAR T-cell Meeting.

]]>

An overview of the CAR T-cell therapy story

Fri, 26 Feb 2021 14:08:22 +0000

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an overview of the CAR T-cell therapy story so far. The introduction of CAR T-cell therapy was a real revolution in the field of hematology. Following the breakthrough clinical results in the pivotal trials, the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) have approved two anti-CD19 CAR T-cell products: tisagenlecleucel for the use in children and young adults up to 25 years of age with relapsed/refractory (R/R) acute lymphoblastic leukemia, and tisagenlecleucel and axicabtagene ciloleucel for the use in adult patients with R/R diffuse large B-cell lymphoma. In addition, several clinical trials are currently investigating the use of CAR T-cells in other hematological malignancies. It is anticipated that other CAR T-cell products will soon be approved. This interview took place during the 3rd European CAR T-cell Meeting.

]]>

Practical aspects of CAR T-cell therapy

Fri, 26 Feb 2021 14:08:21 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, gives an overview of the topics discussed in the session he chaired on practical aspects of CAR T-cell therapy. CAR T-cell immunotherapy has radically altered the treatment of B-cell malignancies. Prof. Jäger outlines that in the setting of diffuse large B-cell lymphoma, the approved CAR-T products are being integrated into daily clinical practice. However, patient selection remains a challenge in the field. The new and exciting field of BCMA CAR T-cells in multiple myeloma was also addressed during the session. This interview took place during the 3rd European CAR T-cell Meeting.

]]>

Updates on CAR T-cell therapy in B-cell malignancies

Fri, 26 Feb 2021 14:08:20 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the progress and future directions in CAR T-cell therapy for the treatment of B-cell malignancies. The availability of CAR-T has altered the current treatment algorithm for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Indications will likely expand to other disease entities and earlier lines of therapy. Future directions include products targeting multiple tumor antigens to overcome resistance. This interview took place during the 3rd European CAR T-cell Meeting.

]]>

CAR-T therapy for aggressive B-cell lymphomas

Thu, 08 Oct 2020 14:08:15 +0000

Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the use of CAR T-cell therapies for patients with aggressive B-cell lymphomas, including tisagenlecleucel and axicabtagene ciloleucel, both approved by the FDA in the third-line setting for patients with aggressive B-cell lymphomas. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]>

Anti-CD19 CAR T-cells for adults

Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults with lymphoma and leukemia, specifically discussing the sustained remissions seen in patients treated with tisagenlecleucel and axicabtagene ciloleucel. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]>

Real-world efficacy & safety data: CAR-T in DLBCL

Thu, 08 Oct 2020 14:08:13 +0000

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory diffuse large B-Cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]>